Takotsubo Cardiomyopathy in Patients Suffering From Acute Non-traumatic Subarachnoid Hemorrhage

Data to be registered within 24 hours after admittance:

• Age of the patient
• Gender
• Comorbidities
• Currently taken medications
• The exact time point of bleeding
• Additional circumstances of the bleeding
• Physical stress factors
• Psychological stress factors
• Significant blood pressure elevation, and its assumed reason
• Severity of bleeding:Fisher's Grade; Neurological status; Hunt-Hess scale;GCS (Glasgow Coma Scale)
• Intracranial blood flow characteristics:TCCD - using Transcranial Color Doppler; systolic, diastolic and mean blood flow velocity, Systolic / Diastolic ratio, pulsatility index
• Cardiac status:Chest pain, Shortness of breath, Pulmonary edema
• ECG abnormalities: Corrected QT Interval (QTc), T wave, ST segment, arrhythmia
• Enzyme level associated with myocardial tissue necrosis: Cardiac troponin I (cTnI), creatine kinase (CK), CK-MB, Brain natriuretic peptide (BNP), N-terminal prohormone of brain natriuretic peptide (NT-proBNP)
• The amount of urine collected in 24 hours and determination of urine metanephrine, normetanephrine levels
• Chest X-ray
• Echocardiography (Ejection fraction%, exact location and degree of cardiac wall motion abnormalities) - documented with video recording
• Medication: Nimodipine, simvastatin, keeping Mg levels in the normal range, ulcer prophylaxis, painkillers
• Fluid therapy: ensuring normovolaemia

Data to be recorded during hospital stay:

• Localization of the bleeding (is there an aneurysm present, if yes what is its location, size)
• Is ventricular drain necessary?
• Treatment methods of the aneurysm:Endovascular, aneurysm clipping
• Time passed between bleeding and treatment (in hours)

The following investigations are repeated daily:

• 12-lead ECG
• Myocardial necrotic enzymes (checked daily over 1 week even if no ECG abnormalities are present) : cardiac troponin I (cTnI), creatine kinase (CK), CK-MB, Brain natriuretic peptide (BNP), N-terminal prohormone of brain natriuretic peptide (NT-proBNP)
• In case of ECG abnormalities echocardiography should take place on the same day (with video recording)
• If there are no ECG abnormalities echocardiography should be controlled once within the first week (with video recording)
• Transcranial Color Doppler (TCCD)
• Glasgow Coma Scale (GCS)
• Recording the currently used medicines with accurate doses (with special attention to the positive inotropic agents and drugs with vasoconstrictor properties)
• In case of mechanical ventilation:Fraction of inspired oxygen (FiO 2), Positive end expiratory pressure (PEEP), Blood gas analysis (PaO 2, PaCO 2), Peak pressure (PPeak)
• Noting the presence of pulmonary edema (auscultation, blood gas analysis) If Takotsubo cardiomyopathy is diagnosed, the 24-hour urine collection test should be repeated (measure the quantity of collected urine, determine urine metanephrine and normetanephrine levels)

The following diagnostic steps should be repeated after 1 month:

• Echocardiography
• 12-lead ECG
• New York Heart Association scores (NYHA scores)
• Glasgow outcome scale (GOS) - survival index
• Bartel Index, Karnofsky score - index of life quality
• The amount of urine collected in 24 hours and determination of urine metanephrine, normetanephrine levels

If echocardiography shows cardiac wall motion abnormality, cardiac examination should be carried out as the following:

• Cardiac stress test if necessary
• CT coronary angiogram if necessary
• Coronary angiography if necessary

The following examinations should be carried out after 6 months:

• Echocardiography
• 12-lead ECG
• New York Heart Association scores (NYHA scores)
• Glasgow outcome scale (GOS) - survival index
• Bartel Index
• The amount of urine collected in 24 hours and determination of urine metanephrine, normetanephrine levels

Comments:

The level of metanephrine and normetanephrine from 24-hour collected urine should be measured again after 1 and 6 months in case of patients where TS was diagnosed.

The urine of patients who have no diagnosed TS will be solely collected and serve as a control. Only 15 of these urine samples will be randomly measured to metanephrine / normetanephrine.

Patient's age, sex, comorbidities, medications, the exact time point of bleeding, the circumstances of bleeding neurological and cardiological status are recorded, laboratory tests, Transcranial Color Doppler (TCCD), echocardiography and chest X-ray examinations are carried out within 24 hours after the patient is being admitted to the ICU.

The medication to prevent vasospasm (Nimodipine, Simvastatin, sustained physiological Mg level) and ulcers, just like the drugs to relief pain are the same in case of all patients.

The goal of fluid therapy is to maintain normovolaemia. The location of the bleeding is recorded (is there any aneurysm, its size is measured; if ventricular drainage is necessary, the method that used to treat aneurysm: endovascular, clipping; time elapsed between bleeding and therapy) 12-lead ECG, cardiac enzymes, TCCD measurement, neurological state, medications and its doses, blood gas analysis in case of mechanical ventilation and ventilation parameters are carried out and recorded on a daily basis.

Cardiac ultrasound and 12-lead ECG examinations are carried out, NYHA scores, clinical outcome (GOS), quality of life (Bartel Index) and Karnofsky scores are recorded after 1 month.

If echocardiography shows cardiac wall motion abnormality, cardiac examination should be carried out as following: cardiac stress test, coronary CT angiogram and coronary angiography if necessary.

Echocardiography, 12-lead ECG examinations are repeated and NYHA scores, clinical outcome (GOS), quality of life (Bartel Index) and Karnofsky scores are recorded after 6 months.

Inclusion criteria

• Acute subarachnoid hemorrhage
• Admittance to the neurosurgery intensive care unit within 48 hours after the bleeding has occurred
• Over 18 years of age
• No prior cardiological diseases in medical history

Exclusion criteria

• Known myocardial diseases (previous myocardial infarction)
• Preexisting heart failure
• Previously known structural heart disease (severe, clinically significantvalve insufficiency, and / or significant stenosis)
• Preexisting myocarditis
• Preexisting phaecromocytoma
• Preexisting hypertrophic cardiomyopathy (Left ventricle > 15 mm)
• Preexisting coronary artery stenosis that requires dilation (patients should be excluded if coronary artery stenosis with dilation need is confirmed during the follow-up period)